| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | intravenous infusion |
| Reference number | 4453 |
| Indication | In combination with chemotherapy for the neoadjuvant treatment of early-stage (stage IB-IIIA) operable non-small cell lung cancer (NSCLC) |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | TA876 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer |
| Commercial arrangement | PAS |